Genetic screening test, genetic screening down syndrome, Ninalia NIPT

NIPT by Biomnis The new prenatal trisomy screening test based on maternal blood sample

Trisomy 13

Download the brochure

Genetic screening test

Non-Invasive Genetic Screening Tests Rule Out Common Pregnancy Risks

Testing for potential fetal abnormalities is recommended for women with higher genetic risks. The most commonly prescribed procedure is a Down Syndrome screening test, generally carried out by analyzing fetal fluid through amniocentesis. But this procedure is not without risk: while the chances of losing the fetus are small, it remains a concern. In response, Eurofins Biomnis has developed non-invasive genetic screening tests that deliver fast and accurate results. Their NIPT (non-invasive prenatal testing) kit draws analysis from a maternal blood sample. By choosing a non-invasive genetic screening test, it can be determined whether the risk of fetal chromosomal disorders is high or low, reducing invasive procedures by up to 95%.

Although pregnancy risks get plenty of media coverage, expectant parents are often ill-informed about their screening and assessment options, believing that to undergo a genetic screening tests during pregnancy, they must choose among invasive and potentially risky medical procedures. But while amniocentesis tests for trisomy carry some non-negligible risks, effective non-invasive options are now readily available. By opting for a Eurofins Biomnis NIPT test, you can significantly reduce or eliminate the need for complicated and invasive prenatal screenings. Safe, reliable, and rapid, these innovative genetic screening tests during pregnancy can be obtained starting in only the tenth week of pregnancy. They simultaneously detect risks for trisomies 13, 18 and 21.

To effectively rule out those risks, scheduling non-invasive genetic screening for Down Syndrome with a primary care physician or other healthcare provider offers patients and expectant parents genuine peace of mind. Non-invasive genetic testing during pregnancy helps patients and practitioners mitigate the risks associated with more traditional prenatal screening procedures. The genetic screening for Down Syndrome developed by EurofinsBiomnis can be easily prescribed and administered, carried out by your healthcare provider or at a EurofinsBiomnis partner laboratory. During your consultation, your doctor will prescribe an NIPT and ask you to sign an informed consent form. The procedure is quick and painless, and results are available within around seven working days.

Can Patau Syndrome really be detected prenatally without relying on invasive testing methods? The answer is yes. The genetic screening for Patau Syndrome offered by EurofinsBiomnis is remarkably accurate, offering a detection rate of over 99%. This allows healthcare providers tofrequently eliminate all need to undergo invasive forms of diagnosis. How does this work? Besides maternal DNA, the blood of pregnant women contains fetal DNA. The NIPT test uses an innovative technology to determine whether a trisomy is present. Thanks to these ground-breaking developments, genetic screening for Patau Syndrome can be carried out with minimal risk.

Advantages of NIPT by Biomnis

> 99 % Detection rateof NIPT test 1 Single blood sample 10 Available from week 10of amenorrhoea 7 Results availablewithin 7 working days 95 % Can minimize unnecessary invasive sampling by 95%